
Deion Sanders' bladder cancer diagnosis sounds the alarm for testing
When he announced Monday that he had undergone surgery in June to remove his bladder after a cancer diagnosis, it once again became evident that cancer doesn't discriminate around wealth and status.
But the serious nature of his condition highlights concerns about how Black people tend to be at a disproportionately higher health risk than other groups due to the deficiencies in care. Doctors hope Sanders' diagnosis can influence others to take preventative steps.
Geoffrey Mount Varner, an emergency room physician in Maryland, noted that Black people are less likely to get bladder cancer but are more likely to die from it. 'It does impact Black people more and aggressively,' he said.
In a video of Sanders, 57, filmed in May but shared by his son on Sunday, the coach spoke about how emotionally and mentally draining it was to have to write a will before his surgery.
'That's not easy at all,' he said at the time.
A high-profile figure like Sanders having a cancerous tumor on his bladder is likely to prompt more people to seek screening. Five years ago, the shocking death of actor Chadwick Boseman from colon cancer at age 43 raised awareness among Black men of the importance of having a colonoscopy. Black people are at a disproportionately high risk for colon cancer diagnoses, according to the American Cancer Society, and the mortality rate has increased in recent years, particularly among Black men.
Just four days before Sanders' press conference, Varner, also a Black man in his 50s, completed chemotherapy for prostate cancer.
'Cancer touches 100% of people,' Varner said.
What is bladder cancer surgery like?
During the press conference, Janet Kukreja, the director of urological oncology at University of Colorado Health, said Sanders chose to have bladder surgery over chemotherapy because it increased his chances to continue coaching.
'It's a laparoscopic surgery,' Kukreja, who performed the surgery, said, 'where we attach a robot to the patient, and then we do all the maneuvering of the robot, and then once the bladder comes out, we also take some lymph nodes to make sure it hasn't spread — and it didn't — and then we make a new bladder for people. 'We use their own intestine so they don't have to take immunosuppression.
Life after the surgery, she said, 'is a new way of life, and it is a learning curve, for sure.'
Sanders, who plans to coach the Buffaloes in the upcoming season, even joked that there may need to be a 'port-a-potty on the sideline.'
Philippe Spiess, a genitourinary oncologist at Moffitt Cancer Center in Tampa, Florida, said this procedure typically lasts between five and seven hours and 'involves removing the bladder, prostate and surrounding lymph nodes in the pelvis,' since the cancer could spread beyond the bladder.'
Why Black Americans should take note
Sanders used the Monday press conference to urge those watching to 'get checked out,' especially when there are even the mildest of symptoms that something is off.
It was sound advice, Varner said.
'One of the screen exams for bladder cancer is, for instance, just a regular urinalysis,' he said. 'It will pick up blood in the urine, which is a symptom. If you don't go to your primary care physician and have these basic screenings done, you miss it. And by the time you have obvious symptoms, you're further along the line for prostate cancer or colon cancer or breast cancer for Black women.'
Varner said up to 70% of cancers are tied to food consumption, especially fast food and ultraprocessed products.
'In Black communities, there are one and a half times more fast-food restaurants,' he said. 'The reason why that matters is that fast food restaurants serve hyperprocessed foods, which leads to or increases the risk of cancer. And so right off the bat, it puts Black folks at a disadvantage.'
'It would help all people, and the Black community specifically, if some of the basic screenings were free,' Varner said.
As an ER doctor, Varner said he often sees patients who have long had symptoms of a serious illness, but by the time they get to the hospital, 'they want immediate care.' But earlier screening would make the issue of care a little less invasive and daunting.
Varner said prostate-specific screenings for cancer and analysis should be more broadly accessible. 'There are programs that help with the cost of some tests,' he said. 'But we have to take advantage of them and not wait until it's too late.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


USA Today
2 hours ago
- USA Today
Her doctor said her tumor was harmless, common among Black women. It was cancer.
Tamron Little was 21 and pregnant with her first child. During a routine ultrasound, doctors found what they suspected to be a fibroid tumor. Little's tumor wasn't tested or treated – doctors told her this type of tumor was common among Black women and would resolve on its own, but they were wrong. Five months after giving birth, she was diagnosed with peritoneal mesothelioma, a rare and aggressive cancer that affects the lining of the abdomen and, in most cases, develops following asbestos exposure. Her misdiagnosis had delayed treatment, and just as she was starting her journey as a new mother, she was given 18 months to live. Little, now 39 and a contributor for the Mesothelioma Center at survived. But her misdiagnosis led to a distrust in the medical system. Each year, a misdiagnosed disease kills or disables about 795,000 people in the United States, according to a 2023 study published by BMJ Quality & Safety. In a July 2024 survey of 50 cancer survivors across the U.S. who were misdiagnosed, 92% said the misdiagnosis hurt their health, 64% had their treatment delayed, and 56% said their cancer advanced to a later stage. 'Not in a million years' could it be cancer When Little's tumor was first discovered and misidentified as a fibroid, she shared the news with her family. Her mom told her it was fine; she had them too. Her aunt, who also had fibroids, said, 'It's just something that you live with.' Instead, Little attributed her symptoms to her first pregnancy, even when she became severely anemic. 'I still thought, 'OK, pregnancy is brutal,'' she says. Her anemia symptoms became so severe that Little dropped out of college and moved back home. After she had her son, her OBGYN placed her on birth control in an attempt to shrink the suspected fibroid tumor. A few months had passed, and a routine ultrasound showed that the tumor was getting larger. That was the first time cancer crossed Little's mind. "Right in that moment, I asked the doctor, 'I know you're saying that this is a fiber tumor. Could this be cancer?'" she says. The doctor reassured her: "No, not in a million years," she recalls. "You're healthy, and for women of childbearing age, fibroids are very common." But out of caution, the doctor decided to take the tumor out. Finally, she was diagnosed with peritoneal mesothelioma. 'I looked at my family members, and their world just crushed,' she says. 'That is when I became the eye of the storm.' They called in the grief counselor. Little was given a prognosis of 18 months to live. She was in shock. All she wanted to do was hug her baby. 'I went in there thinking, 'Oh, this is just a routine procedure to get a fibroid tumor out,' and I came out with a cancer diagnosis of a cancer I've never heard of before,' she recalls. Her doctor had no treatment plan. She searched for a second opinion and found, at the time, one of the few doctors on the East Coast who specialized in HIPEC (hyperthermic intraperitoneal chemotherapy), a two-step procedure that involves inserting high doses of chemotherapy directly into the abdomen. Black women are more likely to die from multiple cancers, despite differing incidence rates Black women have a higher risk of death than their White counterparts when it comes to certain cancers, such as breast cancer and cervical cancer, which have been studied at length. In a 2022 study of 50 Black women who had experienced perceived discrimination in medical settings, 94% of participants felt like they were receiving poorer service during medical visits, and 92% believed they were not being listened to or 'taken seriously.' In 2025, an estimated 319,750 people will be diagnosed with breast cancer in the U.S., and an estimated 42,680 people will die from the disease. While there has been an overall 44% decrease in breast cancer deaths since 1989, the mortality gap between Black and White women remains. Compared to White women, Black women have a 4% lower incidence rate of breast cancer, but a 40% higher death rate, according to the American Cancer Society. And despite differences in incidence rates across the lifespan – Black women are more likely than white women to have breast cancer before the age of 45, but less likely between the ages of 60 to 84 – Black women are still more likely to die from breast cancer at every age. Black women also have higher incidence and death rates of cervical cancer compared to white women; their 5-year survival rate (56%) is 10% lower than the national average. Early diagnosis is crucial in treatment, but White women are twice as likely to be screened for cervical cancer than Black women. A delayed diagnosis can further hinder the care a patient receives. 'It's something that is very disheartening,' Little says of her misdiagnosis. 'But it's something that as a woman of color, I've experienced time after time.' Misdiagnosis leads to decreased trust in the medical system From the Tuskegee Syphilis Study to the forced sterilization of Black women throughout the 20th century, race-based medical malpractice has been well-documented in U.S. history. In a 2024 study, 58% of Black women surveyed believed the medical system was "designed to hold Black people back." While Little survived, her trust in the medical system faltered. Eighteen years later, she's still 'very strategic' when it comes to choosing her doctors and sets high expectations for their standard of care. 'I've had doctors that, when I asked a question about my platelet counts, said, 'Black women are known to have lower platelet counts than White women,'' she says, referencing her anemia that went dismissed. 'I'm not going to take that for an answer.' Little's family relies on her now, too. When her grandma was diagnosed with colon cancer in 2023, Little was put on FaceTime with her doctors to ask the 'right questions.' 'I can just imagine my other counterparts, women of color, who go through that every day, but may not know how to respond to it, or may think that that's normal,' she says. 'You have a right as a patient to respectfully disagree with your doctor, and you have a right to lay those expectations down beforehand.'


Los Angeles Times
13 hours ago
- Los Angeles Times
Rethinking Multiple Sclerosis: Why Everything We Thought We Knew Is Changing
The story we used to tell about multiple sclerosis was simple. Clean. Maybe a little too clean. We taught it in lecture halls and explained it to patients. The script was always the same: MS is an autoimmune disease where the body's T-cells—the special forces of the immune system—go rogue. They mistake the nervous system for an invader and attack the myelin sheath, the fatty insulation that keeps our nerve signals moving fast. Strip away that insulation, you get short circuits. Relapses. Disability. It was a neat narrative. T-cells were the clear villain. But the real world is messy. And the clues that our story was wrong came from our own treatments. New therapies came along that absolutely hammered B-cells—another part of the immune army we'd mostly ignored in the MS story. And they worked. Frighteningly well [4]. That begged a huge question. If this was a T-cell war, why was taking out the B-cell infantry so brutally effective? It forced a complete reset. Turns out, B-cells aren't just standing around. They're key players, maybe even the ringleaders that get the T-cells riled up and keep the fires of chronic inflammation burning [1] [2]. This wasn't some minor academic correction. It changed everything. It meant our entire working model of the disease was incomplete. We'd been staring at one piece of the puzzle, thinking it was the whole picture. The neat story was wrong. This disease is a product of a murky conspiracy between a person's genes and some environmental trigger we still can't nail down [3] [10]. A virus from childhood? A chronic deficiency? We have a list of suspects, but no convictions. What we do know is that once it kicks off, it's a cascade of damage. And it's not just about the myelin anymore. It's about the nerve itself. The wire, not just the insulation. First job is getting the diagnosis right. For that, we have the MRI. It's our window into the damage [9]. We hunt for lesions—the scars of past attacks—in the brain and spinal cord. But one picture isn't enough. To be sure it's MS, we have to prove the damage is happening in different places and at different times. Dissemination in space and time. That's the mantra. The McDonald criteria are the rules of the game for this, and they've been sharpened over the years to be faster and more accurate [13]. The 2017 update, for example, cut down the waiting time for a diagnosis. Good. Because time is brain. The sooner we know, the sooner we can act. We even have advanced imaging now that lets us see past the obvious lesions to the subtle, fraying wires underneath it all [15]. But the sharper picture from our MRIs showed us something else. Something uncomfortable. The old textbooks taught us MS was a disease of white people with Northern European roots. That was the classic patient profile. Another part of our simple story. And another part that was dead wrong [8]. The data coming out now paints a very different picture. In the United States, Black individuals don't just get MS—they have the highest incidence of the disease [14]. Hispanic communities are also hit hard. This isn't a footnote. It's the headline. It tells us that MS risk is shaped by more than just ancestry. It's shaped by society. It's about where you live, your access to care, and the systemic biases baked into the world [14]. It's a humbling reality check. A disease doesn't happen in a biological vacuum. It happens in the real world [7]. The last two decades? An absolute explosion in treatments [2] [5]. We went from having almost nothing to a whole arsenal of drugs. The new high-efficacy therapies, especially those B-cell killers, can slam the brakes on relapses and new MRI lesions [4]. They are powerful weapons against the inflammatory part of MS. But stopping the inflammation, we're learning, is only half the job. MS isn't one thing. It's two. A two-headed monster. It is an inflammatory disease, yes. But it is also a neurodegenerative one [2] [6]. From day one, nerve fibers are being quietly damaged and permanently lost. Axonal transection. That's the technical term. It means the nerve fiber is cut. It doesn't grow back. This is the stealthy process that drives progressive disability, the slow worsening that can happen even when a person feels fine. For years, we saw this as a two-act play: an early, inflammatory stage, followed by a later, degenerative stage. Another simple story. Also wrong. We now know they are partners in crime. Inflammation and neurodegeneration are happening at the same time, a vicious cycle running from day one [12]. This changes the mission entirely. The new mandate isn't just to cool down the immune system. It's to protect the brain itself. Neuroprotection. That's the holy grail now [11] [12]. We need drugs that not only stop the attacks but also shield the neurons from the fallout and, maybe, help the brain heal itself. We aren't there yet. But that's where everything is headed. The goalpost moves. It's not just 'no new attacks' anymore. It's 'save the brain.' Preserve function for the long haul. It means we have to finally toss out the simple stories and face the complicated, challenging reality of what this disease truly is. [1] Yamout, B. I., & Alroughani, R. (2018). Multiple Sclerosis. Seminars in neurology, 38(2), 212–225. [2] Hauser, S. L., & Cree, B. A. C. (2020). Treatment of Multiple Sclerosis: A Review. The American journal of medicine, 133(12), 1380–1390.e2. [3] Ghasemi, N., Razavi, S., & Nikzad, E. (2017). Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy. Cell journal, 19(1), 1–10. [4] Galota, F., Marcheselli, S., De Biasi, S., Gibellini, L., Vitetta, F., Fiore, A., Smolik, K., De Napoli, G., Cardi, M., Cossarizza, A., & Ferraro, D. (2025). Impact of High-Efficacy Therapies for Multiple Sclerosis on B Cells. Cells, 14(8), 606. [5] Martin, R., Sospedra, M., Rosito, M., & Engelhardt, B. (2016). Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis. European journal of immunology, 46(9), 2078–2090. [6] McGinley, M. P., Goldschmidt, C. H., & Rae-Grant, A. D. (2021). Diagnosis and Treatment of Multiple Sclerosis: A Review. JAMA, 325(8), 765–779. [7] Kapica-Topczewska, K., Kulakowska, A., Kochanowicz, J., & Brola, W. (2025). Epidemiology of multiple sclerosis: global trends, regional differences, and clinical implications. Neurologia i neurochirurgia polska, 10.5603/pjnns.103955. Advance online publication. [8] Dobson, R., & Giovannoni, G. (2019). Multiple sclerosis - a review. European journal of neurology, 26(1), 27–40. [9] Elahi, R., Taremi, S., Najafi, A., Karimi, H., Asadollahzadeh, E., Sajedi, S. A., Rad, H. S., & Sahraian, M. A. (2025). Advanced MRI Methods for Diagnosis and Monitoring of Multiple Sclerosis (MS). Journal of magnetic resonance imaging : JMRI, 10.1002/jmri.29817. Advance online publication. [10] Jakimovski, D., Bittner, S., Zivadinov, R., Morrow, S. A., Benedict, R. H., Zipp, F., & Weinstock-Guttman, B. (2024). Multiple sclerosis. Lancet (London, England), 403(10422), 183–202. [11] Thompson, A. J., Baranzini, S. E., Geurts, J., Hemmer, B., & Ciccarelli, O. (2018). Multiple sclerosis. Lancet (London, England), 391(10130), 1622–1636. [12] Coclitu, C. I., Constantinescu, C. S., & Tanasescu, R. (2025). Neuroprotective strategies in multiple sclerosis: a status update and emerging paradigms. Expert review of neurotherapeutics, 25(7), 791–817. [13] Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., Correale, J., Fazekas, F., Filippi, M., Freedman, M. S., Fujihara, K., Galetta, S. L., Hartung, H. P., Kappos, L., Lublin, F. D., Marrie, R. A., Miller, A. E., Miller, D. H., Montalban, X., Mowry, E. M., … Cohen, J. A. (2018). Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet. Neurology, 17(2), 162–173. [14] Langer-Gould, A. M., Cepon-Robins, T. J., Benn Torres, J., Yeh, E. A., & Gildner, T. E. (2025). Embodiment of structural racism and multiple sclerosis risk and outcomes in the USA. Nature reviews. Neurology, 21(7), 370–382. [15] Sbardella, E., Tona, F., Petsas, N., & Pantano, P. (2013). DTI Measurements in Multiple Sclerosis: Evaluation of Brain Damage and Clinical Implications. Multiple sclerosis international, 2013, 671730.
Yahoo
17 hours ago
- Yahoo
Short, Brisk Walks Could Help You Live Longer Than Long, Slow Strolls
The speed of your steps could make a significant difference in adding years to your life, according to a new study. Researchers led by a team from Vanderbilt University in the US analyzed the physical activity of 79,856 adults in 12 US states, comparing links between time spent walking slowly, time spent walking quickly, and eventual cause of death (where applicable) across an average follow-up period of almost 17 years. The data showed that those people who spent at least a quarter of an hour each day walking briskly were significantly less likely to die during the study period, especially from cardiovascular disease. What makes the findings particularly useful is they're based on a sample that includes people typically underrepresented in walking studies like this: the cohort was predominantly made up of low-income and Black individuals, who are often more likely to live in impoverished areas and less likely to have access to safe walking spaces. Related: "Our research has shown that fast walking as little as 15 minutes a day was associated with a nearly 20 percent reduction in total mortality, while a smaller reduction in mortality was found in association with more than three hours of daily slow walking," says epidemiologist Wei Zheng, from Vanderbilt University "This benefit remained strong even after accounting for other lifestyle factors and was consistent across various sensitivity analyses." The researchers categorized slow walking as walking the dog, or walking around at work. To qualify for the faster walking linked to the reduction in the risk of death, it had to be something like climbing stairs or walking briskly as part of an exercise routine. While the study isn't comprehensive enough to show direct cause and effect, the drop in mortality risk is significant enough to strongly suggest some kind of link, and the researchers think the benefits that aerobic exercise brings to heart health is key. Fast walking makes the heart work harder, improving cardiovascular health. Burning calories can also help people stick to a healthy weight. "While the health benefits of daily walking are well established, limited research has investigated the effects of factors such as walking pace on mortality, particularly in low-income and Black/African-American populations," says Zheng. One of the reasons that researchers are so keen to promote walking as a way of staying healthy is that it's just about the simplest exercise out there: most of us can do it, without any special equipment, and it's relatively easy to roll into a daily routine (try parking a little further away from work, for example). "Public health campaigns and community-based programs can emphasize the importance and availability of fast walking to improve health outcomes, providing resources and support to facilitate increased fast walking within all communities," says epidemiologist Lili Liu, from Vanderbilt University. The research has been published in the American Journal of Preventative Medicine. Related News 5 Things You Ought to Know Before Buying Supplements There's One Simple Method to Reduce Alcohol Intake, Scientists Say, And It Works Untested Peptide Injections Are Being Sold as 'Next-Gen Biohacks' Solve the daily Crossword